90. THROMBOGENICS: www.thrombogenics.com

ThromboGenics Ltd is a privately held company founded in Dublin, Ireland in 1998, focused on discovery and development of biotherapeutics for treatment of vascular diseases (including cardiovascular, cerebrovascular and peripheral vascular disease). ThromboGenics' founder and CEO is Désiré Collen, M.D., Ph.D., a world-renowned expert in cardiovascular disease. Prof. Collen directs the Molecular and Cardiovascular Medicine Group at University of Leuven, Belgium, which provides much of the initial research for ThromboGenics programs. Professor Collen's laboratory was the first to produce clinical supply of tissue plasminogen activator (tPA), one of the most effective drugs for thrombolytic therapy of acute myocardial infarction (heart attack). This proprietary molecule is licensed to Genentech in return for royalties on worldwide sales.

Recently, our development of improved ES cell derivation methods, have generated us the possibility to derive ES cells from any mouse strain. These improved ES cell derivation methods even allow the derivation of ES cells from mice strains that were previously considered as non-permissive for ES cell derivation. All derived cell lines have proven germ-line transmission capability at high passage numbers. Among the future research aims of Thromb-X, are the derivation of embryonic stem cells from non-murine species (rabbit, rat, pig), the nuclear transfer technique to produce genetically modified rabbits, and the establishment of pronuclear injection in pigs.

If you are interested in applying to ThromboGenics, please contact us or send your resume to:

Karen Cauwels

ThromboGenics NV

Herestraat 49

B-3000 Leuven

Belgium

Tel: +32 (16) 34 61 94

Fax: +32 (16) 34 61 34

E-mail: karen.cauwels@thrombogenics.com